The clinical translation of gold(I) pharmacophores for liver cancer is hindered by rapid deactivation, poor tumor selectivity, and off-target toxicity. To address these limitations, we engineered a tumor-targeting bovine serum albumin (BSA)-based nanoarchitect... ...

请注册登录后继续浏览